Cardiovascular Disease Microbiome Research & Preclinical Probiotic CRO Services

Creative Biolabs provides cardiovascular disease microbiome research and preclinical probiotic CRO services, helping R&D teams connect candidate strains with phenotype-specific efficacy, metabolite mechanisms, and safety evidence. Our integrated approach combines microbial characterization, cardiometabolic models, short-chain fatty acid testing, metabolomics, and inflammatory readouts to support informed development decisions across hypertension, atherosclerosis, and related indications.

Overview

From Cardiovascular Risk Biology to Testable Microbiome Interventions

Cardiovascular phenotypes do not share one microbiome mechanism. Blood-pressure regulation, lipid-associated plaque formation, and post-ischemic recovery can involve different host pathways, microbial communities, and circulating metabolites. For cardiovascular biotech, metabolic microbiome developers, and functional nutrition R&D teams, a uniform probiotic screening assay can therefore miss the biology that matters most to a particular program.

A useful development plan links a defined strain or microbial function to measurable host outcomes while controlling for diet, baseline microbiota, and model context. Creative Biolabs supports that translation with integrated microbiome mapping, strain-level functional testing, targeted metabolite analysis, and indication-matched preclinical studies—so promising signals can be challenged, prioritized, and interpreted with appropriate safeguards.

Mechanistic research axis

Gut microbiotaStrain identity
community structure
Microbial productsSCFAs · bile acids
TMAO pathways
Host responseVascular · lipid
immune endpoints

Coherent evidence connects changes in microbial function with relevant cardiovascular endpoints.

Hypertension

Integrate blood pressure profiles, vascular reactivity, sodium-handling biology, and microbial metabolite exposure.

Atherosclerosis & Dyslipidemia

Relate lipid panels and lesion biology to inflammatory signaling, barrier function, and selected metabolite pathways.

Cardiac Injury & Remodeling

Where indicated, examine tissue injury, cardiac function, systemic inflammation, and post-injury microbial ecology.

Integrated CRO capabilities

Preclinical Cardiovascular Probiotic Research Services

We align each work package with a defined cardiovascular phenotype and decision point, instead of assuming that the same bacterial endpoint predicts every disease outcome. Study modules can be commissioned individually or combined into a connected research program.

01 / Profile

Cardiovascular Microbiome Mapping & Candidate Prioritization

Characterize disease-associated microbial patterns and nominate candidates based on biologically justified pathways rather than species abundance alone. Molecular data can be integrated with clinical covariates or preclinical phenotype strata when available.

  • 16S rRNA or metagenomic community profiling, differential abundance, and functional pathway hypotheses.
  • Candidate ranking across SCFA metabolism, bile acid signaling, lipid-associated functions, and pro-inflammatory microbial features.
  • Deliverables: microbiome signatures, candidate shortlist, biomarker hypotheses, and model-specific validation plan.
02 / Screen

Probiotic Strain Identification, Functional Screening & Safety Review

Progress from a taxonomy label to an evaluable biological candidate. Creative Biolabs can assess strain identity, functional properties, and potential hazards relevant to the intended research setting.

  • Strain authentication, genomic review, growth and viability, and metabolite-generation assays.
  • Focused assays for cholesterol-assimilation or bile salt hydrolase activity where hypothesis-relevant; host interaction and inflammatory markers as appropriate.
  • Deliverables: strain evaluation matrix, assay methods, comparative results, and a prioritized go/no-go recommendation.
03 / Evaluate

Indication-Matched Animal Efficacy & Host-Response Studies

Choose an established cardiometabolic model or a customized design according to the primary question and feasibility. Measures are prespecified with suitable controls and consideration of sex, diet, microbiota background, and time course.

  • Blood pressure, serum lipids, glucose-related markers, vascular or tissue histology, and selected cardiac functional endpoints.
  • Circulating cytokines, oxidative stress, epithelial barrier readouts, and tolerability observations as appropriate.
  • Deliverables: study plan, prespecified endpoints, curated datasets, and integrated efficacy-versus-mechanism interpretation.
04 / Explain

SCFA Quantification, Metabolomics & Mechanism-of-Action Studies

Determine whether microbial changes correspond to a measurable biochemical pathway and host effect. Targeted and discovery-level metabolite data help separate pathway plausibility from unsupported efficacy claims.

  • Targeted acetate, propionate, and butyrate panels; optional bile acids, tryptophan-derived compounds, and TMAO-related measurements.
  • Metabolomic discovery and follow-up validation, linked with microbiome composition and inflammatory or vascular endpoints.
  • Deliverables: analytical output tables, pathway associations, prioritized markers, and hypotheses for causal validation.

With compatible work packages, we can support the transition from candidate discovery to model-based efficacy and mechanistic investigation in a single coordinated study plan.

Candidate organisms

Research-Relevant Probiotic Strains & Microbial Functional Groups

The original cardiovascular research scope highlights lactic acid bacteria and bifidobacteria in lipid and blood-pressure studies. These organisms are starting points for strain-specific verification—not interchangeable cardiovascular therapeutics.

Lacticaseibacillus casei (formerly Lactobacillus casei)

Investigated in metabolic and fermented-food research; screening should confirm strain-specific lipid, metabolite, and immune phenotypes.

Lactiplantibacillus plantarum (formerly Lactobacillus plantarum)

A candidate for testing dietary lipid-related activity and inflammatory mechanisms, with outcomes dependent on the selected strain.

Lactobacillus helveticus / Lactobacillus research

Fermented-food and bioactive peptide hypotheses can be evaluated in controlled assays; antihypertensive potential cannot be generalized across strains.

Streptococcus thermophilus / Streptococcus research

Primarily a fermented-food starter organism; relevant studies require product-context assessment and organism-specific safety considerations.

Bifidobacterium spp.

Includes strains considered in lipid metabolism and gut-barrier studies. Candidate identity and the metabolite mechanism should be verified directly.

Roseburia spp. & Faecalibacterium spp.

Butyrate-associated community members can serve as functional or ecological research signals; abundance does not imply intervention efficacy.

Decision-ready datasets

Cardiovascular Probiotic Efficacy, Metabolite & Safety Readouts

A prespecified endpoint plan links each research question to an assay, biological matrix, appropriate controls, and the next development decision. The exact panel is tailored to the chosen model.

Research question Illustrative readouts Deliverable / decision
Does the microbiome respond? 16S or metagenomic profiles; strain tracking; community function; time-course sampling Ecological exposure and response profile
Does microbial metabolism shift? Acetate, propionate, butyrate; optional bile acids, tryptophan metabolites, TMAO-related markers Targeted pathway evidence and metabolite priority list
Does a cardiovascular phenotype change? Blood pressure; cholesterol fractions; vascular lesions; selected cardiac functional measures Phenotype-specific efficacy assessment
Are inflammatory pathways affected? TNF-α, IL-6, oxidative stress, endothelial or barrier-associated endpoints as indicated Mechanistic response and context-dependent interpretation
Is the candidate suitable to advance? Strain identity, microbial quality, genomic hazards, susceptibility, tolerability, exposure Integrated safety observations and next-step decision

Assay availability, sample matrices, acceptance criteria, and endpoint selection are specified for each project; the listed outcomes are research endpoints, not guaranteed clinical effects.

Research workflow

Preclinical Cardiovascular Microbiome Study Workflow

1

Define the Phenotype

Specify target indication, hypothesis, matrix, comparators, and success criteria.

2

Select & Characterize

Authenticate candidate strains; profile the microbiome and baseline function.

3

Build the Model

Choose cardiometabolic models, study arms, dosing, and sampling time points.

4

Measure Host Effects

Capture efficacy, inflammatory, vascular, and tolerability endpoints.

5

Analyze Metabolites

Integrate SCFAs, metabolomics, and organism-level findings.

6

Decide & Document

Deliver interpreted datasets, study limitations, and next-step options.

At every phase, a defined decision gate connects assay performance and biological plausibility with the next planned experiment, reducing fragmented readouts and premature conclusions.

Evidence supporting study design

Published Data: Microbiome Remodeling in Cardiovascular Injury Models

Recently published research investigated whether a defined Lactobacillus johnsonii strain could modify gut microbiota and host outcomes in a rat model of acute myocardial infarction. The investigators linked echocardiography, tissue pathology, intestinal barrier measures, microbial composition, and circulating metabolites. Their experimental findings showed differences in cardiac function and inflammatory injury markers alongside microbial remodeling following strain administration. Importantly, the results came from a preclinical rat model and cannot be assumed to predict human cardiovascular benefit.

These findings illustrate why cardiovascular probiotic programs benefit from coordinated strain, metabolite, and host-phenotype assessment rather than relying on microbiome abundance changes alone. Creative Biolabs supports this evidence-building approach through candidate screening, phenotype-matched animal studies, targeted SCFA analysis, broader metabolomics, and safety-oriented study planning. Research designs can test whether shifts in intestinal barrier and metabolite signatures accompany meaningful, reproducible host outcomes, while separating mechanistic association from causal demonstration.

Proposed links between Lactobacillus-mediated microbiome remodeling, gut barrier changes, metabolites and myocardial outcomes in rats. (OA Literature)
Fig.1 Graphical abstract: gut microbiome remodeling and cardiovascular outcomes after Lactobacillus johnsonii administration in an acute myocardial infarction model.1,2
Why Creative Biolabs

Advantages of Our Cardiovascular Probiotic Research Platform

Phenotype-Specific Strategies

Models and endpoints follow the cardiovascular question rather than a generic gut-health readout.

Integrated Omics & SCFAs

Microbiome, targeted metabolites, and host biology are measured within a coherent plan.

Strain-Level Reproducibility

Identity and function checkpoints make results traceable to an actual candidate organism.

Mechanism-Aware Design

Potential SCFA, inflammatory, and barrier pathways are tested against predefined outcomes.

Transparent Development Gates

Clear controls, QA, study limitations, and decision criteria support program reviews.

Flexible CRO Collaboration

Targeted standalone analytics or integrated end-to-end work packages can be scoped.

Complementary capabilities

Recommended Services for Cardiovascular Microbiome Studies

These related services can be combined with the core cardiovascular program to add model-specific efficacy evaluation, targeted SCFA measures, broader metabolic profiling, and mechanism-linked analytics.

03
Short Chain Fatty Acid (SCFA) Analysis Services

Targeted acetate, propionate, and butyrate endpoints

04
Comprehensive Metabolomic Profiling Service for Gut Microbiota Research

Untargeted discovery and targeted metabolite follow-up

Frequently Asked Questions

We first define the primary phenotype—blood pressure regulation, dyslipidemia or atherosclerosis, or post-ischemic remodeling—then select models, exposure windows, comparators, and endpoints matched to that question. Microbiome composition and metabolite profiles are interpreted alongside host outcomes rather than being treated as efficacy evidence on their own.

Targeted panels can quantify acetate, propionate, and butyrate in fecal or biological matrices appropriate to the study. Broader profiling may include bile acids, amino acid-derived products, and trimethylamine N-oxide (TMAO) where method suitability and matrix validation support the assay. We predefine normalization, quality controls, and the limits of interpretation.

Yes. Candidate strains can undergo identity confirmation, genomic and safety review, functional screening, and carefully controlled preclinical evaluation. Species-level associations do not establish strain-specific cardiovascular benefit; evidence is generated separately for each proposed strain and indication.

Controls can include vehicle and model controls, baseline samples, a justified positive comparator, and appropriate dietary or exposure standardization. Where mechanistic attribution matters, additional microbiota-perturbation or metabolite-rescue arms may be considered if scientifically suitable.

Study planning can include strain identity, antimicrobial susceptibility and relevant genomic hazards, tolerability, microbial translocation or barrier endpoints where indicated, plus dose and exposure tracking. The resulting evidence supports a research go/no-go decision; it does not itself demonstrate clinical safety or treatment efficacy.

References

  1. Zhong, Xinqin, et al. "Remodeling of the gut microbiome by Lactobacillus johnsonii alleviates the development of acute myocardial infarction." Frontiers in Microbiology 14 (2023): 1140498. https://doi.org/10.3389/fmicb.2023.1140498
  2. Distributed under Open Access license CC BY 4.0, without modification.
Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Creative Biolabs-Live Biotherapeutics


ISO 9001 Certified - Creative Biolabs Quality Management System.
Contact us

Copyright © 2026 Creative Biolabs. All Rights Reserved.

Inquiry Basket
Close